Skip to main content

Miquel Raspall Chaure

Institutions of which they are part

Pediatric Neurology
Vall Hebron Institut de Recerca

Miquel Raspall Chaure

Institutions of which they are part

Pediatric Neurology
Vall Hebron Institut de Recerca

Projects

Neurologia infantil

IP: Alfons Macaya Ruíz
Collaborators: Laia Ventura i Expósito, Belen Perez Dueñas, Laura Costa Comellas, Ainara Salazar Villacorta, Francina Munell Casadesus, Miquel Raspall Chaure, Mireia del Toro Riera, Julia Sala Coromina, Ana Felipe Rucián, Ana Laura Cazurro Gutierrez, David Gómez Andrés, Amaia Lasa Aranzasti, Lucy Dougherty de Miguel
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 01171
Duration: 01/01/2022 - 30/06/2025

Evaluation of NGS candidate genes causality in developmental epileptic encephalopathiea

IP: Alfons Macaya Ruíz
Collaborators: Miquel Raspall Chaure, Mireia del Toro Riera, Julia Sala Coromina, Ana Felipe Rucián
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI20/01803
Duration: 01/01/2021 - 31/12/2023

Neurologia Pediàtrica (GRC)

IP: Alfons Macaya Ruíz
Collaborators: Susana Boronat Guerero, Francina Munell Casadesus, Maria Jose Pérez García, Miquel Raspall Chaure, Mireia del Toro Riera, Marta Vila Pueyo
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2014 SGR 1087
Duration: 01/01/2014 - 31/12/2016

Secuenciación exómica en el estudio molecular de las encefalopatías epilépticas de inicio precoz

IP: Alfons Macaya Ruíz
Collaborators: Miquel Raspall Chaure, Marta Vila Pueyo
Funding agency: Instituto de Salud Carlos III
Funding: 98615
Reference: PI12/01005
Duration: 01/01/2013 - 31/12/2015

Related news

The ClinPrior algorithm achieved a positive diagnosis rate of 70% in two minority diseases of neurodegenerative origin, which represents double the number of cases that are diagnosed with current tools.

Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.

El 20% dels pacients en els quals s’havia trobat alguna predisposició genètica van ser diagnosticats amb algun tipus de tumor i van poder iniciar el tractament de manera precoç.

Related professionals

David Gurwitz

David Gurwitz

Senior researcher
Systemic Diseases
Read more
SILVIA GARTNER TIZZANO

SILVIA GARTNER TIZZANO

Main researcher
Growth and Development
Read more
Luca Basile

Luca Basile

Administration and Management
Microbiology
Read more
Ana  Leon  Espitia

Ana Leon Espitia

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.